Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Nov 10 - Nov 15
(2012) demonstrated: Statistically significant reductions in visceral adipose tissue of approximately 1518% over 26 weeks compared to placebo Meaningful increases in IGF-1 levels Improvements in triglyceride profiles in some patient subgroups Effects were partially reversed upon discontinuation, suggesting that sustained benefit requires ongoing therapy The consistency of the VAT reduction finding across multiple trials is what anchors tesamorelin's clinical utility
doi: 10.1038/nrendo.2016.90 73 HuffnagelICLahejiFKAziz-BoseRTritosNAMarinoRLinthorstGEet al
"This causes you to lose weight as you eat less
Common adverse effects include nausea (occurring in approximately 44% of patients according to clinical trials), vomiting, diarrhoea, constipation, and abdominal discomfort
US$ 21.25
US$ 21.90
US$ 25.62
US$ 27.17
